After huge anticipation, Wegovy’s oral tablet launched in the U.S. this January. By February, nearly 200,000 people were already using the pill. Health economists estimate it could add approximately $2.76 billion to overall Wegovy sales by 2030, with its share growing from about 3% in 2026 to 17% by 2031. At first glance, this momentum may suggest the pill is preferred over the once-weekly injection. However, that is not necessarily the case. Many individuals continue to prefer an injectable option, particularly when it better aligns with their routine or expectations. The choice between oral and injectable therapy is not straightforward.…